Favorable safety and efficacy profiles of α-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-versus-host disease of the gastrointestinal tract: a retrospective, single center study | Synapse
April 25, 2026Open Access
Favorable safety and efficacy profiles of α-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-versus-host disease of the gastrointestinal tract: a retrospective, single center study
Key Points
This research investigates the safety and efficacy of α-1-antitrypsin in treating acute graft-versus-host disease affecting the gastrointestinal tract.
Retrospective study design
Single-center analysis
Assessment of α-1-antitrypsin in steroid- and ruxolitinib-refractory cases.
Reported favorable safety profile for α-1-antitrypsin in treated patients.
Improved clinical outcomes were noted in patients unresponsive to standard treatments.